“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Concern is growing among Democrats after President Donald Trump reversed some of the former president's executive orders, including efforts to reduce prescription drug costs for Medicare and Medicaid beneficiaries.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

As President Donald Trump’s health care agenda for a second term takes shape, it’s becoming clear that many Biden-era policies won’t make the cut.

President Trump rescinded a Biden-era Executive Order that would have lowered the copays for some drugs to $2 for Medicare enrollees.